Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 518

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Pseudomonas aeruginosa Biofilms in Disease

Open access
Mulcahy, Lawrence R., Isabella, Vincent M., Lewis, Kim·2014·Microbial Ecology
DOI 10.1007/s00248-013-0297-xPMC PMC3977026
Open this paper in CoChat — free account

Abstract

Pseudomonas aeruginosa is a ubiquitous organism that is the focus of intense research because of its prominent role in disease. Due to its relatively large genome and flexible metabolic capabilities, this organism exploits numerous environmental niches. It is an opportunistic pathogen that sets upon the human host when the normal immune defenses are disabled. Its deadliness is most apparent in cystic fibrosis patients, but it also is a major problem in burn wounds, chronic wounds, chronic obstructive pulmonary disorder, surface growth on implanted biomaterials, and within hospital surface and water supplies, where it poses a host of threats to vulnerable patients (Peleg and Hooper, N Engl J Med 362:1804–1813, 2010; Breathnach et al., J Hosp Infect 82:19–24, 2012). Once established in the patient, P. aeruginosa can be especially difficult to treat. The genome encodes a host of resistance genes, including multidrug efflux pumps (Poole, J Mol Microbiol Biotechnol 3:255–264, 2001) and enzymes conferring resistance to beta-lactam and aminoglycoside antibotics (Vahdani et al., Annal Burns Fire Disast 25:78–81, 2012), making therapy against this gram-negative pathogen particularly challenging due to the lack of novel antimicrobial therapeutics (Lewis, Nature 485: 439–440, 2012). This challenge is compounded by the ability of P. aeruginosa to grow in a biofilm, which may enhance its ability to cause infections by protecting bacteria from host defenses and chemotherapy. Here, we review recent studies of P. aeruginosa biofilms with a focus on how this unique mode of growth contributes to its ability to cause recalcitrant infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00248-013-0297-x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 111

  1. Peleg AY, Hooper DC (2010) Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 362(19):1804–1813. doi: 10.1056/NEJMra0904124 · DOI · Paper page
  2. Breathnach AS, Cubbon MD, Karunaharan RN, Pope CF, Planche TD (2012) Multidrug-resistant Pseudomonas aeruginosa outbreaks in two hospitals: association with contaminated hospital waste-water systems. The Journal of hospital infection 82(1):19–24. doi: 10.1016/j.jhin.2012.06.007 · doi:10.1016/j.jhin.2012.06.007
  3. Poole K (2001) Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 3(2):255–264
  4. Vahdani M, Azimi L, Asghari B, Bazmi F, Rastegar Lari A (2012) Phenotypic screening of extended-spectrum ss-lactamase and metallo-ss-lactamase in multidrug-resistant Pseudomonas aeruginosa from infected burns. Annals of burns and fire disasters 25(2):78–81
  5. Lewis K (2012) Antibiotics: recover the lost art of drug discovery. Nature 485(7399):439–440. doi: 10.1038/485439a · DOI · Paper page
  6. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G (2003) The application of biofilm science to the study and control of chronic bacterial infections. The Journal of clinical investigation 112(10):1466–1477 · DOI · Paper page
  7. Gristina AG, Costerton JW (1985) Bacterial adherence to biomaterials and tissue. The significance of its role in clinical sepsis. The Journal of bone and joint surgery American volume 67(2):264–273 · DOI · Paper page
  8. Cross A, Allen JR, Burke J, Ducel G, Harris A, John J, Johnson D, Lew M, MacMillan B, Meers P et al (1983) Nosocomial infections due to Pseudomonas aeruginosa: review of recent trends. Reviews of infectious diseases 5(Suppl 5):S837–S845 · DOI · Paper page
  9. Peters G, Locci R, Pulverer G (1981) Microbial colonization of prosthetic devices. II. Scanning electron microscopy of naturally infected intravenous catheters. Zentralbl Bakteriol Mikrobiol Hyg [B] 173(5):293–299
  10. Ganderton L, Chawla J, Winters C, Wimpenny J, Stickler D (1992) Scanning electron microscopy of bacterial biofilms on indwelling bladder catheters. Eur J Clin Microbiol Infect Dis 11(9):789–796 · DOI
  11. Raad I, Hanna H (1999) Intravascular catheters impregnated with antimicrobial agents: a milestone in the prevention of bloodstream infections [see comments]. Support Care Cancer 7(6):386–390 · DOI
  12. Adair CG, Gorman SP, Feron BM, Byers LM, Jones DS, Goldsmith CE, Moore JE, Kerr JR, Curran MD, Hogg G, Webb CH, McCarthy GJ, Milligan KR (1999) Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Med 25(10):1072–1076 · DOI · Paper page
  13. Vandecandelaere I, Matthijs N, Van Nieuwerburgh F, Deforce D, Vosters P, De Bus L, Nelis HJ, Depuydt P, Coenye T (2012) Assessment of microbial diversity in biofilms recovered from endotracheal tubes using culture dependent and independent approaches. PLoS One 7(6):e38401. doi: 10.1371/journal.pone.0038401 · DOI
  14. Frank DN, Wilson SS, St Amand AL, Pace NR (2009) Culture-independent microbiological analysis of foley urinary catheter biofilms. PLoS One 4(11):e7811. doi: 10.1371/journal.pone.0007811 · DOI
  15. Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168(8):918–951 · DOI · Paper page
  16. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG (2008) A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci U S A 105(39):15070–15075. doi: 10.1073/pnas.0804326105 · DOI · Paper page
  17. Sibley CD, Parkins MD, Rabin HR, Surette MG (2009) The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis. Curr Opin Investig Drugs 10(8):787–794
  18. Sibley CD, Grinwis ME, Field TR, Eshaghurshan CS, Faria MM, Dowd SE, Parkins MD, Rabin HR, Surette MG (2011) Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS One 6(7):e22702. doi: 10.1371/journal.pone.0022702 · DOI · Paper page
  19. Klepac-Ceraj V, Lemon KP, Martin TR, Allgaier M, Kembel SW, Knapp AA, Lory S, Brodie EL, Lynch SV, Bohannan BJ, Green JL, Maurer BA, Kolter R (2010) Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ Microbiol 12(5):1293–1303. doi: 10.1111/j.1462-2920.2010.02173.x · DOI · Paper page
  20. Rose LM, Neale R (2010) Development of the first inhaled antibiotic for the treatment of cystic fibrosis. Science translational medicine 2(63):63mr64. doi: 10.1126/scitranslmed.3001634 · doi:10.1126/scitranslmed.3001634
  21. Hurley MN, Ariff AH, Bertenshaw C, Bhatt J, Smyth AR (2012) Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. Journal of cystic fibrosis 11(4):288–292. doi: 10.1016/j.jcf.2012.02.006 · DOI · Paper page
  22. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP (2000) Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407(6805):762–764. doi: 10.1038/35037627 · DOI · Paper page
  23. Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Hoiby N (2009) Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatric pulmonology 44(6):547–558. doi: 10.1002/ppul.21011 · DOI · Paper page
  24. No authors (1999) Consensus Development Conference on Diabetic Foot Wound Care: 7–8 April 1999, Boston, Massachusetts. American Diabetes Association. Diabetes care 22 (8):1354–1360
  25. James GA, Swogger E, Wolcott R, Pulcini E, Secor P, Sestrich J, Costerton JW, Stewart PS (2008) Biofilms in chronic wounds. Wound repair and regeneration 16(1):37–44. doi: 10.1111/j.1524-475X.2007.00321.x · DOI · Paper page
  26. Fazli M, Bjarnsholt T, Kirketerp-Moller K, Jorgensen B, Andersen AS, Krogfelt KA, Givskov M, Tolker-Nielsen T (2009) Nonrandom distribution of Pseudomonas aeruginosa and Staphylococcus aureus in chronic wounds. J Clin Microbiol 47(12):4084–4089. doi: 10.1128/JCM.01395-09 · DOI · Paper page
  27. Burmolle M, Thomsen TR, Fazli M, Dige I, Christensen L, Homoe P, Tvede M, Nyvad B, Tolker-Nielsen T, Givskov M, Moser C, Kirketerp-Moller K, Johansen HK, Hoiby N, Jensen PO, Sorensen SJ, Bjarnsholt T (2010) Biofilms in chronic infections—a matter of opportunity—monospecies biofilms in multispecies infections. FEMS immunology and medical microbiology 59(3):324–336. doi: 10.1111/j.1574-695X.2010.00714.x · DOI · Paper page
  28. Hoyle BD, Alcantara J, Costerton JW (1992) Pseudomonas aeruginosa biofilm as a diffusion barrier to piperacillin. Antimicrob Agents Chemother 36(9):2054–2056 · DOI · Paper page
  29. Nichols WW, Evans MJ, Slack MP, Walmsley HL (1989) The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa. J Gen Microbiol 135(5):1291–1303
  30. Tetz GV, Artemenko NK, Tetz VV (2009) Effect of DNase and antibiotics on biofilm characteristics. Antimicrob Agents Chemother 53(3):1204–1209. doi: 10.1128/AAC.00471-08 · DOI · Paper page
  31. Stewart PS (1996) Theoretical aspects of antibiotic diffusion into microbial biofilms. Antimicrob Agents Chemother 40(11):2517–2522 · DOI · Paper page
  32. Lu X, Roe F, Jesaitis A, Lewandowski Z (1998) Resistance of biofilms to the catalase inhibitor 3-amino-1,2,4-triazole. Biotechnol Bioeng 60(1):135. doi: 10.1002/(SICI)1097-0290(19981005)60:1<135::AID-BIT15>3.0.CO;2-P · DOI
  33. Fux CA, Costerton JW, Stewart PS, Stoodley P (2005) Survival strategies of infectious biofilms. Trends Microbiol 13(1):34–40. doi: 10.1016/j.tim.2004.11.010 · DOI · Paper page
  34. Vrany JD, Stewart PS, Suci PA (1997) Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics. Antimicrob Agents Chemother 41(6):1352–1358 · DOI
  35. Stone G, Wood P, Dixon L, Keyhan M, Matin A (2002) Tetracycline rapidly reaches all the constituent cells of uropathogenic Escherichia coli biofilms. Antimicrob Agents Chemother 46(8):2458–2461 · DOI
  36. Anderl JN, Zahller J, Roe F, Stewart PS (2003) Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 47(4):1251–1256 · DOI · Paper page
  37. Bagge N, Hentzer M, Andersen JB, Ciofu O, Givskov M, Hoiby N (2004) Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 48(4):1168–1174 · DOI · Paper page
  38. Walters MC 3rd, Roe F, Bugnicourt A, Franklin MJ, Stewart PS (2003) Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 47(1):317–323 · DOI · Paper page
  39. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K (2013) Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 339(6124):1213–1216. doi: 10.1126/science.1232688 · DOI · Paper page
  40. Purdy Drew KR, Sanders LK, Culumber ZW, Zribi O, Wong GC (2009) Cationic amphiphiles increase activity of aminoglycoside antibiotic tobramycin in the presence of airway polyelectrolytes. J Am Chem Soc 131(2):486–493. doi: 10.1021/ja803925n · DOI
  41. Chiang WC, Nilsson M, Jensen PO, Hoiby N, Nielsen TE, Givskov M, Tolker-Nielsen T (2013) Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 57(5):2352–2361. doi: 10.1128/AAC.00001-13 · DOI · Paper page
  42. deBeer D, Stoodley P, Lewandowski Z (1997) Measurement of local diffusion coefficients in biofilms by microinjection and confocal microscopy. Biotechnology and Bioengineering 53(2):151–158. doi: 10.1002/(Sici)1097-0290(19970120)53:2<151::Aid-Bit4>3.0.Co;2-N · DOI · Paper page
  43. Takenaka S, Pitts B, Trivedi HM, Stewart PS (2009) Diffusion of macromolecules in model oral biofilms. Appl Environ Microbiol 75(6):1750–1753. doi: 10.1128/AEM.02279-08 · DOI · Paper page
  44. Moser C, Kjaergaard S, Pressler T, Kharazmi A, Koch C, Hoiby N (2000) The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. Apmis 108(5):329–335. doi: 10.1034/j.1600-0463.2000.d01-64.x · DOI · Paper page
  45. Hartl D, Griese M, Kappler M, Zissel G, Reinhardt D, Rebhan C, Schendel DJ, Krauss-Etschmann S (2006) Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 117(1):204–211. doi: 10.1016/j.jaci.2005.09.023 · DOI · Paper page
  46. Moss RB, Hsu YP, Olds L (2000) Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol 120(3):518–525 · doi:10.1046/j.1365-2249.2000.01232.x
  47. Moser C, Johansen HK, Song Z, Hougen HP, Rygaard J, Hoiby N (1997) Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. Apmis 105(11):838–842 · DOI
  48. Moser C, Hougen HP, Song Z, Rygaard J, Kharazmi A, Hoiby N (1999) Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response. Apmis 107(12):1093–1100 · doi:10.1111/j.1699-0463.1999.tb01514.x
  49. Johansen HK, Hougen HP, Rygaard J, Hoiby N (1996) Interferon-gamma (IFN-gamma) treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats. Clin Exp Immunol 103(2):212–218 · DOI
  50. Schnyder-Candrian S, Strieter RM, Kunkel SL, Walz A (1995) Interferon-alpha and interferon-gamma down-regulate the production of interleukin-8 and ENA-78 in human monocytes. J Leukoc Biol 57(6):929–935 · DOI
  51. Jensen PO, Moser C, Kobayashi O, Hougen HP, Kharazmi A, Hoiby N (2004) Faster activation of polymorphonuclear neutrophils in resistant mice during early innate response to Pseudomonas aeruginosa lung infection. Clin Exp Immunol 137(3):478–485. doi: 10.1111/j.1365-2249.2004.02554.xCEI2554 · DOI
  52. Alhede M, Bjarnsholt T, Jensen PO, Phipps RK, Moser C, Christophersen L, Christensen LD, van Gennip M, Parsek M, Hoiby N, Rasmussen TB, Givskov M (2009) Pseudomonas aeruginosa recognizes and responds aggressively to the presence of polymorphonuclear leukocytes. Microbiology 155(Pt 11):3500–3508. doi: 10.1099/mic.0.031443-0 · DOI · Paper page
  53. Jensen PO, Bjarnsholt T, Phipps R, Rasmussen TB, Calum H, Christoffersen L, Moser C, Williams P, Pressler T, Givskov M, Hoiby N (2007) Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 153(Pt 5):1329–1338. doi: 10.1099/mic.0.2006/003863-0 · DOI · Paper page
  54. Jensen PO, Givskov M, Bjarnsholt T, Moser C (2010) The immune system vs. Pseudomonas aeruginosa biofilms. FEMS Immunol Med Microbiol 59(3):292–305. doi: 10.1111/j.1574-695X.2010.00706.x · DOI · Paper page
  55. Leid JG, Willson CJ, Shirtliff ME, Hassett DJ, Parsek MR, Jeffers AK (2005) The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killing. J Immunol 175(11):7512–7518 · DOI · Paper page
  56. Wood LF, Ohman DE (2012) Identification of genes in the sigma(2)(2) regulon of Pseudomonas aeruginosa required for cell envelope homeostasis in either the planktonic or the sessile mode of growth. MBio 3 (3). doi: 10.1128/mBio.00094-12 · DOI
  57. Van Gennip M, Christensen LD, Alhede M, Phipps R, Jensen PO, Christophersen L, Pamp SJ, Moser C, Mikkelsen PJ, Koh AY, Tolker-Nielsen T, Pier GB, Hoiby N, Givskov M, Bjarnsholt T (2009) Inactivation of the rhlA gene in Pseudomonas aeruginosa prevents rhamnolipid production, disabling the protection against polymorphonuclear leukocytes. Apmis 117(7):537–546. doi: 10.1111/j.1600-0463.2009.02466.x · DOI · Paper page
  58. van Gennip M, Christensen LD, Alhede M, Qvortrup K, Jensen PO, Hoiby N, Givskov M, Bjarnsholt T (2012) Interactions between polymorphonuclear leukocytes and Pseudomonas aeruginosa biofilms on silicone implants in vivo. Infect Immun 80(8):2601–2607. doi: 10.1128/Iai.06215-11 · DOI
  59. Kharazmi A (1991) Mechanisms involved in the evasion of the host defense by Pseudomonas aeruginosa. Immunol Lett 30(2):201–206. doi: 10.1016/0165-2478(91)90026-7 · DOI
  60. Wagner VE, Li LL, Isabella VM, Iglewski BH (2007) Analysis of the hierarchy of quorum-sensing regulation in Pseudomonas aeruginosa. Analytical and Bioanalytical Chemistry 387(2):469–479. doi: 10.1007/s00216-006-0964-6 · DOI
  61. Pier GB, Coleman F, Grout M, Franklin M, Ohman DE (2001) Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis. Infect Immun 69(3):1895–1901. doi: 10.1128/Iai.69.3.1895-1901.2001 · DOI · Paper page
  62. Lewenza S (2013) Extracellular DNA-induced antimicrobial peptide resistance mechanisms in Pseudomonas aeruginosa. Front Microbiol 4:21. doi: 10.3389/fmicb.2013.00021 · DOI
  63. Moskowitz SM, Ernst RK (2010) The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection. Subcell Biochem 53:241–253. doi: 10.1007/978-90-481-9078-2_11 · DOI
  64. Xu KD, McFeters GA, Stewart PS (2000) Biofilm resistance to antimicrobial agents. Microbiology 146(Pt 3):547–549
  65. Evans DJ, Brown MR, Allison DG, Gilbert P (1990) Susceptibility of bacterial biofilms to tobramycin: role of specific growth rate and phase in the division cycle. J Antimicrob Chemother 25(4):585–591 · DOI
  66. Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A (1986) The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 132(Pt 5):1297–1304
  67. Gilbert P, Collier PJ, Brown MR (1990) Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob Agents Chemother 34(10):1865–1868 · DOI · Paper page
  68. NCCLS (2002) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd edn. CLSI document M27-A2. NCCLS, Wayne
  69. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A (1999) The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37(6):1771–1776 · DOI · Paper page
  70. Moskowitz SM, Foster JM, Emerson J, Burns JL (2004) Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42(5):1915–1922 · DOI · Paper page
  71. Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, Katz MF, Ahrens R, Hornick D, Joseph PM, Gibson RL, Aitken ML, Benton WW, Burns JL (2011) Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatric pulmonology 46(2):184–192. doi: 10.1002/ppul.21350 · DOI
  72. Spoering AL, Lewis K (2001) Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. Journal of bacteriology 183(23):6746–6751. doi: 10.1128/JB.183.23.6746-6751.2001 · DOI · Paper page
  73. Palmer RJ Jr, Stoodley P (2007) Biofilms 2007: broadened horizons and new emphases. J Bacteriol 189(22):7948–7960 · DOI
  74. Lewis K (2008) Multidrug tolerance of biofilms and persister cells. Current topics in microbiology and immunology 322:107–131
  75. Percival SL, Hill KE, Malic S, Thomas DW, Williams DW (2011) Antimicrobial tolerance and the significance of persister cells in recalcitrant chronic wound biofilms. Wound Repair Regen 19(1):1–9. doi: 10.1111/j.1524-475X.2010.00651.x · DOI · Paper page
  76. Simoes LC, Lemos M, Pereira AM, Abreu AC, Saavedra MJ, Simoes M (2011) Persister cells in a biofilm treated with a biocide. Biofouling 27(4):403–411. doi: 10.1080/08927014.2011.579599 · DOI
  77. Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, McKay G, Siehnel R, Schafhauser J, Wang Y, Britigan BE, Singh PK (2011) Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 334(6058):982–986. doi: 10.1126/science.1211037 · DOI · Paper page
  78. Bernier SP, Lebeaux D, DeFrancesco AS, Valomon A, Soubigou G, Coppee JY, Ghigo JM, Beloin C (2013) Starvation, together with the SOS response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin. PLoS genetics 9(1):e1003144. doi: 10.1371/journal.pgen.1003144 · DOI · Paper page
  79. Dorr T, Vulic M, Lewis K (2010) Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS biology 8(2):e1000317. doi: 10.1371/journal.pbio.1000317 · DOI · Paper page
  80. Liu Y, Imlay JA (2013) Cell death from antibiotics without the involvement of reactive oxygen species. Science 339(6124):1210–1213. doi: 10.1126/science.1232751 · DOI · Paper page
  81. Breidenstein EB, de la Fuente-Nunez C, Hancock RE (2011) Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19(8):419–426. doi: 10.1016/j.tim.2011.04.005 · DOI · Paper page
  82. Liao J, Sauer K (2012) The MerR-like transcriptional regulator BrlR contributes to Pseudomonas aeruginosa biofilm tolerance. J Bacteriol 194(18):4823–4836. doi: 10.1128/JB.00765-12 · DOI
  83. Liao J, Schurr MJ, Sauer K (2013) The MerR-like regulator BrlR confers biofilm tolerance by activating multidrug-efflux pumps in Pseudomonas aeruginosa biofilms. J Bacteriol. doi: 10.1128/JB.00318-13 · DOI
  84. Brooun A, Liu S, Lewis K (2000) A dose–response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 44(3):640–646 · DOI · Paper page
  85. Stewart PS, Franklin MJ (2008) Physiological heterogeneity in biofilms. Nat Rev Microbiol 6(3):199–210 · DOI · Paper page
  86. Sonnleitner E, Abdou L, Haas D (2009) Small RNA as global regulator of carbon catabolite repression in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 106(51):21866–21871. doi: 10.1073/pnas.pnas.0910308106 · DOI · Paper page
  87. O’Toole GA, Gibbs KA, Hager PW, Phibbs PV Jr, Kolter R (2000) The global carbon metabolism regulator Crc is a component of a signal transduction pathway required for biofilm development by Pseudomonas aeruginosa. J Bacteriol 182(2):425–431 · DOI · Paper page
  88. Linares JF, Moreno R, Fajardo A, Martinez-Solano L, Escalante R, Rojo F, Martinez JL (2010) The global regulator Crc modulates metabolism, susceptibility to antibiotics and virulence in Pseudomonas aeruginosa. Environ Microbiol 12(12):3196–3212. doi: 10.1111/j.1462-2920.2010.02292.x · DOI · Paper page
  89. Zhang L, Chiang WC, Gao Q, Givskov M, Tolker-Nielsen T, Yang L, Zhang G (2012) The catabolite repression control protein Crc plays a role in the development of antimicrobial-tolerant subpopulations in Pseudomonas aeruginosa biofilms. Microbiology 158(Pt 12):3014–3019. doi: 10.1099/mic.0.061192-0 · DOI
  90. Amini S, Hottes AK, Smith LE, Tavazoie S (2011) Fitness landscape of antibiotic tolerance in Pseudomonas aeruginosa biofilms. PLoS pathogens 7(10):e1002298. doi: 10.1371/journal.ppat.1002298 · DOI
  91. Mena A, Smith EE, Burns JL, Speert DP, Moskowitz SM, Perez JL, Oliver A (2008) Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 190(24):7910–7917. doi: 10.1128/JB.01147-08 · DOI · Paper page
  92. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D’Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103(22):8487–8492. doi: 10.1073/pnas.0602138103 · DOI · Paper page
  93. Mulcahy LR, Burns JL, Lory S, Lewis K (2010) Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. Journal of bacteriology 192(23):6191–6199. doi: 10.1128/JB.01651-09 · DOI · Paper page
  94. De Groote VN, Verstraeten N, Fauvart M, Kint CI, Verbeeck AM, Beullens S, Cornelis P, Michiels J (2009) Novel persistence genes in Pseudomonas aeruginosa identified by high-throughput screening. FEMS microbiology letters 297(1):73–79. doi: 10.1111/j.1574-6968.2009.01657.x · DOI
  95. Moker N, Dean CR, Tao J (2010) Pseudomonas aeruginosa increases formation of multidrug-tolerant persister cells in response to quorum-sensing signaling molecules. Journal of bacteriology 192(7):1946–1955. doi: 10.1128/JB.01231-09 · DOI · Paper page
  96. De Groote VN, Fauvart M, Kint CI, Verstraeten N, Jans A, Cornelis P, Michiels J (2011) Pseudomonas aeruginosa fosfomycin resistance mechanisms affect non-inherited fluoroquinolone tolerance. J Med Microbiol 60(Pt 3):329–336. doi: 10.1099/jmm.0.019703-0 · DOI
  97. Maisonneuve E, Shakespeare LJ, Jorgensen MG, Gerdes K (2011) Bacterial persistence by RNA endonucleases. Proceedings of the National Academy of Sciences of the United States of America 108(32):13206–13211. doi: 10.1073/pnas.1100186108 · DOI · Paper page
  98. Watters C, DeLeon K, Trivedi U, Griswold JA, Lyte M, Hampel KJ, Wargo MJ, Rumbaugh KP (2013) Pseudomonas aeruginosa biofilms perturb wound resolution and antibiotic tolerance in diabetic mice. Medical microbiology and immunology 202(2):131–141. doi: 10.1007/s00430-012-0277-7 · DOI
  99. Gurjala AN, Geringer MR, Seth AK, Hong SJ, Smeltzer MS, Galiano RD, Leung KP, Mustoe TA (2011) Development of a novel, highly quantitative in vivo model for the study of biofilm-impaired cutaneous wound healing. Wound repair and regeneration 19(3):400–410. doi: 10.1111/j.1524-475X.2011.00690.x · DOI · Paper page
  100. Seth AK, Geringer MR, Galiano RD, Leung KP, Mustoe TA, Hong SJ (2012) Quantitative comparison and analysis of species-specific wound biofilm virulence using an in vivo, rabbit-ear model. Journal of the American College of Surgeons 215(3):388–399. doi: 10.1016/j.jamcollsurg.2012.05.028 · DOI · Paper page
  101. Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, Taft PJ, Rogan MP, Pezzulo AA, Karp PH, Itani OA, Kabel AC, Wohlford-Lenane CL, Davis GJ, Hanfland RA, Smith TL, Samuel M, Wax D, Murphy CN, Rieke A, Whitworth K, Uc A, Starner TD, Brogden KA, Shilyansky J, McCray PB Jr, Zabner J, Prather RS, Welsh MJ (2008) Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 321(5897):1837–1841. doi: 10.1126/science.1163600 · DOI · Paper page
  102. Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MH, Ramachandran S, Moninger TO, Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M, Banfi B, Horswill AR, Stoltz DA, McCray PB Jr, Welsh MJ, Zabner J (2012) Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487(7405):109–113. doi: 10.1038/nature11130 · DOI · Paper page
  103. Chauhan A, Lebeaux D, Ghigo JM, Beloin C (2012) Full and broad-spectrum in vivo eradication of catheter-associated biofilms using gentamicin-EDTA antibiotic lock therapy. Antimicrob Agents Chemother 56(12):6310–6318. doi: 10.1128/AAC.01606-12 · DOI
  104. Wolcott RD, Kennedy JP, Dowd SE (2009) Regular debridement is the main tool for maintaining a healthy wound bed in most chronic wounds. Journal of wound care 18(2):54–56 · DOI · Paper page
  105. Wolcott RD, Rumbaugh KP, James G, Schultz G, Phillips P, Yang Q, Watters C, Stewart PS, Dowd SE (2010) Biofilm maturity studies indicate sharp debridement opens a time- dependent therapeutic window. Journal of wound care 19(8):320–328 · DOI · Paper page
  106. Dowd SE, Wolcott RD, Kennedy J, Jones C, Cox SB (2011) Molecular diagnostics and personalised medicine in wound care: assessment of outcomes. Journal of wound Care 20(5):232, 234–239 · DOI
  107. Hoffman LR, Ramsey BW (2013) Cystic fibrosis therapeutics: the road ahead. Chest 143(1):207–213. doi: 10.1378/chest.12-1639 · DOI
  108. Kaneko Y, Thoendel M, Olakanmi O, Britigan BE, Singh PK (2007) The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. The Journal of clinical investigation 117(4):877–888. doi: 10.1172/JCI30783 · DOI · Paper page
  109. Miller C, McMullin B, Ghaffari A, Stenzler A, Pick N, Roscoe D, Ghahary A, Road J, Av-Gay Y (2009) Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. Nitric oxide: biology and chemistry 20(1):16–23. doi: 10.1016/j.niox.2008.08.002 · DOI
  110. Miller C, Miller M, McMullin B, Regev G, Serghides L, Kain K, Road J, Av-Gay Y (2012) A phase I clinical study of inhaled nitric oxide in healthy adults. Journal of cystic fibrosis 11(4):324–331. doi: 10.1016/j.jcf.2012.01.003 · DOI
  111. Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, Ordonez C, Ahrens R (2013) Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. doi: 10.1164/rccm.201301-0153OC · DOI · Paper page

Cited by

See all 518

Metadata

Authors
Mulcahy, L. R., Isabella, V. M., & Lewis, K.
Venue
Microbial Ecology
Publisher
Springer Science and Business Media LLC
Published
2013-10-06
Volume
68
Issue
1
Pages
1-12
ISSN
  • 0095-3628 (ISSN-L)
  • 1432-184X
DOI
10.1007/s00248-013-0297-x
PMC
PMC3977026
OpenAlex
W2038329167
Cited by
518
References
8
FWCI
5.11
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pseudomonas aeruginosa Biofilms in Disease. https://app.cochat.ai/papers/10.1007/s00248-013-0297-x
The paper
Mulcahy, L. R., Isabella, V. M., & Lewis, K. (2014). Pseudomonas aeruginosa Biofilms in Disease. Microbial Ecology. https://doi.org/10.1007/s00248-013-0297-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.